I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Tom King Biography and Net Worth

Director of Medpace

Dr. King is a physician and a board certified Pathologist with a Ph.D. in Molecular Biology and extensive experience as a laboratory director in hospital, academic and corporate settings. Currently Dr. King is the Medical Director at Immunovia, Inc. and an Adjunct Associate Professor in the School of Health Professions at Rutgers, The State University of New Jersey. From 2013 to 2017, Dr. King was the Chief of Pathology and Laboratory Medicine at St. Vincent Hospital in Worcester, Massachusetts. Dr. King was a Partner and Medical Director of Pathology and Laboratory Medicine at University Pathologists, LLC in Providence, Rhode Island from 2009 to 2013, and the Medical Director of Pathology and Laboratory Medicine at the University Medical Group in Providence, Rhode Island from 2007 to 2008. From 2002 to 2003, Dr. King was the Senior Director of Molecular Pathology at Millennium Pharmaceuticals. Additionally, Dr. King has held various positions in academia including at Boston University School of Medicine, Brown University School of Medicine, the University of Connecticut School of Medicine and Washington University Medical Center. Dr. King was a Director and Chair of the Corporate Governance Committee of predecessor entities of the Company from 2004 to 2011. Dr. King received his Bachelor of Arts degree, M.D. and Ph.D. from Washington University in St. Louis.

How do I contact Tom C. King?: The corporate mailing address for Dr. King and other Medpace executives is 5375 MEDPACE WAY, CINCINNATI OH, 45227. Medpace can also be reached via phone at (513) 579-9911 and via email at [email protected]. Learn More on Tom C. King's contact information.
Has Tom C. King been buying or selling shares of Medpace?: Tom C. King has not been actively trading shares of Medpace in the last ninety days. Most recently, Tom C. King sold 176 shares of the business's stock in a transaction on Wednesday, November 3rd. The shares were sold at an average price of $226.63, for a transaction totalling $39,886.88. Learn More on Tom C. King's trading history.
Who are Medpace's active insiders?: Medpace's insider roster includes Kevin Brady (CFO), Susan Burwig (VP), Stephen Ewald (General Counsel), Jesse Geiger (CFO), Ashley Keating (Director), Tom King (Director), Robert Kraft (Director), and August Troendle (CEO). Learn More on Medpace's active insiders.
Are insiders buying or selling shares of Medpace?: In the last twelve months, insiders at the sold shares 11 times. They sold a total of 218,961 shares worth more than $88,468,498.45. The most recent insider tranaction occured on May, 28th when CEO August J Troendle sold 5,695 shares worth more than $2,252,315.55. Insiders at Medpace own 20.3% of the company. Learn More about insider trades at Medpace.
Information on this page was last updated on 5/28/2024.

Tom C. King Insider Trading History at Medpace

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/3/2021	Sell	176	$226.63	$39,886.88
7/29/2021	Sell	226	$175.74	$39,717.24

Tom C. King Buying and Selling Activity at Medpace

Medpace Company Overview

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

Today's Range

Now: $337.28

$334.00

$342.50

50 Day Range

MA: $339.14

$308.93

$363.58

2 Week Range

Now: $337.28

$277.72

$459.77

Volume

683,001 shs

Average Volume

284,230 shs

Market Capitalization

$10.48 billion

P/E Ratio

29.53

Dividend Yield

N/A

Beta

1.37

I was wrong. Dead wrong.

From Porter & Company | Ad